Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy.
about
Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancerCritical analysis of salvage radical prostatectomy in the management of radioresistant prostate cancer.Saudi oncology society and Saudi urology association combined clinical management guidelines for prostate cancer.Saudi Oncology Society clinical management guidelines for prostate cancer.Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database.The changing pattern of management for hormone-refractory, metastatic prostate cancer.Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy.Factors influencing biochemical recurrence in patients who have received salvage radiotherapy after radical prostatectomy: a systematic review and meta-analysis.Circulating tumor cells correlate with patterns of recurrence in patients with hormone-sensitive prostate cancer.Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 casesA phase II trial of a soy beverage for subjects without clinical disease with rising prostate-specific antigen after radical radiation for prostate cancer.Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer.Salvage partial brachytherapy for prostate cancer recurrence after primary brachytherapy.Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for prostate cancer 2017.Prostate cancer recurrence: can PSA guide imaging?
P2860
Q26747782-07E7C610-FEA3-4C48-A355-8EE399307EEFQ33414012-339C454A-4864-4F1F-92EF-9438DCD209B9Q34437308-2E78931D-052A-42B5-B2DB-744D5E51E529Q34997355-9EA117DB-802C-4300-B640-5E6BBAE79FB9Q35231126-E80E867A-E622-4E95-992C-473385A045C1Q36519880-3EE4A81E-05D7-495A-8BAF-498D58F3F887Q37161554-BFC1F454-3E7E-438C-8DF1-16A9026C2E00Q38848538-1EA200A4-D283-434C-82A8-856080893E4EQ41283989-32309D31-AAB1-4689-952F-07AB0F44B339Q41689170-C46623A3-77C9-4C95-9F24-2DC92C976152Q43184865-8FB6E77D-9AC1-486E-99B6-FEC9BF20C04BQ47100267-DDDB477B-12B0-4A32-A2B3-43A2E2624983Q50738805-3D1BA8EE-C1F5-4E88-96E2-D15377666AEFQ55024078-CC4D8BED-F068-4A87-8742-5C9D4F877760Q57780533-C8E9FCBE-7A87-4ACB-970F-9676A6067C16
P2860
Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Utility of prostate-specific a ...... nts for salvage local therapy.
@ast
Utility of prostate-specific a ...... nts for salvage local therapy.
@en
type
label
Utility of prostate-specific a ...... nts for salvage local therapy.
@ast
Utility of prostate-specific a ...... nts for salvage local therapy.
@en
prefLabel
Utility of prostate-specific a ...... nts for salvage local therapy.
@ast
Utility of prostate-specific a ...... nts for salvage local therapy.
@en
P356
P1476
Utility of prostate-specific a ...... nts for salvage local therapy.
@en
P2093
Andrew K Lee
Anthony V D'Amico
P304
P356
10.1200/JCO.2005.03.0007
P407
P577
2005-11-01T00:00:00Z